Arriving on Wednesday, April 6, 2016 for the CBBS Annual Meeting?
There are three industry workshops available beginning at 2:00 PM, all including in your full conference registration fee! Pre-registration is not required.
At 2:00 PM, Cerus Corporation presents:
The Changing Landscape of Blood Safety: A year in review since US Pathogen Reduction approval
A Year in Review – Dr. Larry Corash, Chief Scientific Officer, Cerus
Dr. Corash will provide an update on pathogen reduction and how its adoption has evolved over the year. New developments with regard to the INTERCEPT Blood System, pathogen reduction system will be discussed.
Transfusion-Associated Sepsis – Addressing Under-Reported Bacterial Contamination of Platelets - Dr. Patricia Kopko, Director of Transfusion Medicine at UCSD
Though various procedures have been implemented to improve the safety of platelet components, significant risk is still present with ~50% of contaminated platelet units missed via early culture detection methods. Furthermore, incidences of bacterial contamination and associated sepsis go unrecognized by physicians due to passive surveillance. Dr. Kopko will discuss the challenges that hospitals face in recognizing transfusion-related sepsis. The anticipated impact that the FDA Draft Guidance will have in mitigating this risk will also be discussed.
Improving Plasma Safety and Availability with Pathogen Reduction – Alicia Pritchard – Sr. VP Biologics at OneBlood
Safe, available plasma is essential in treating traumatic injury, one of the top three causes of death in the US. Alicia Pritchard will discuss how pathogen reduction offers a comprehensive strategy in a changing environment where emerging pathogens threaten the blood supply, and the need for immediate, compatible plasma is on the rise. In addition to mitigating transfusion-transmitted infectious risk due to certain arboviruses, pathogen reduction mitigates bacterial contamination risk, enabling the safe use and immediate availability of never frozen liquid plasma. Furthermore, pathogen reduction offers operational efficiencies that may help increase production of AB plasma, a type that’s in high demand in trauma situations where doctors may not know the recipient’s blood type.
At 3:30 PM, two additional industry workshops are available.
The first is from Bio-Rad Laboratories:
Workflow Analysis Using the LSS Roadmap; Comparing Five Methodologies for Type & Screen Testing
Barbara Bachman, MS, MT(ASCP)SBB, MBB (DA), Immunohematology, Blood Bank Specialist
- There are multiple ways one can evaluate test methodologies. The Lean Six Sigma Roadmap provides a structured approach that can significantly assist facilities in better understanding their customer's / facility's needs, as well as provide some additional evaluation tools that can be utilized for method comparison as well as other process improvement activities.
At the end of this session, the participant will be able to:
- Define some of the key principles, roadmap and methods of Lean Six Sigma.
- Apply a portion of the LSS Roadmap to evaluate Blood Group Serology Testing methodologies
- Explain the benefits of using LSS to evaluate automated testing platforms to meet facility goals and requirements.
The third industry workshop, also at 3:30 PM is presented by Fresenius Kabi:
Discussion on the Impact of Platelet Additive Solution
Dr. Catherine Mazzei, Medical Director American Red Cross, Northern California Blood Services Region
Dr. Ingrid Perez-Alvarez, Chief Resident, University of California San Diego Medical Center
Objective: An informative discussion focused on learnings related to the use of platelet additive solutions.
- The session will include a physician’s perspective on how transfusing platelets with platelet additive solution (PAS) can impact patient reactions as well as a blood center’s perspective on how adding PAS to platelet collections can increase the supply of plasma.